Aesica pushes the top three after record year
A North East pharmaceuticals firm - which enjoyed £14.7m profits in 2009 - has been named number three in the Sunday Times Deloitte Buyout Track 100, following the company’s most successful year since it was formed.
The Deloitte list ranks the UK’s top private equity backed companies with the fastest growing profits.
This is the second year in which Aesica has featured in the list, climbing 47 places from last year’s position at number 50.
Aesica secured its place on the list as it profits increased by 106% from £3.5 million in 2007 to £14.7 million in 2009.
Dr Robert Hardy, Chief Executive Officer, Aesica, said: “We have had a very clear strategy in place for expansion over the past 12 months starting with the acquisition of R5 Pharmaceuticals in Nottingham in June 2010 and followed by the acquisition of three European manufacturing sites from UCB, which are due to complete shortly.
“The European acquisitions, which include a long-term strategic partnership with UCB, will result in our workforce almost doubling to approximately 1,300 staff, which will have a significant impact on revenue in 2011.”
The company recruited new business development managers for San Diego and New York in preparation for future expansion across America.
By 2013, Aesica predict sales will tip £300 million.
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.